Skip to main content Accessibility help
  • Print publication year: 2012
  • Online publication date: July 2012

Chapter 15 - Historical perspectives on the use of therapeutic agents to treat neurodevelopmental disorders


Currently available treatments for neurodegenerative diseases are exclusively palliative. In Alzheimer's disease (AD) they are focused on the cholinergic deficit and alterations in glutamate function related to neurotoxicity. Finding drugs that can attenuate or reverse neurodegenerative disease progression is challenging in the absence of a complete understanding of the underlying causes. Biomarkers represent any measure that can be used to indicate the presence of a disease state. Biomarkers are critical both for making an accurate diagnosis of each of the neurodegenerative diseases and for assessing their status and response to treatment. They are crucial for clinical trials from their initial design, to patient recruitment, to establishing objective end points. Neurodegenerative disease-associated genes continue to be identified at an ever-increasing rate using genome-wide association studies (GWAS) in cohorts of affected individuals. A large number of candidate genes and loci identified for neurodegenerative diseases, for example, in excess of 120 for AD.


AndersonGM, FreedmanDX, CohenDJet al. 1987. Whole blood serotonin in autistic and normal subjects. J Child Psychol Psychiatry 28:885–900.
Autism Speaks Press Release 2009. Autism Speaks announces results reported for the Study of Fluoxetine in Autism (SOFIA). [Accessed July 18, 2011].
BarkleyRA, FischerM, EdelbrockCS, SmallishL. 1990. The adolescent outcome of hyperactive children diagnosed by research criteria: I. An 8-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry 29:546–557.
BearMF. 2005. Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes Brain Behav 4:393–398.
BearMF, HuberKM, WarrenST. 2004. The mGluR theory of fragile X mental retardation. Trends Neurosci 27:370–377.
Berry-KravisE, PotanosK. 2004. Psychopharmacology in fragile X syndrome – present and future. Ment Retard Dev Disabil Res Rev 10:42–48.
BiedermanJ, BaldessariniRJ, WrightV, KneeD, HarmatzJS. 1989. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry 28:777–784.
BiedermanJ, FaraoneS, MilbergerSet al. 1996. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 53:437–446.
BradleyC. 1937. The behavior of children receiving Benzedrine. Am J Psychiatry 94:577–585.
BradleyW, BowenC. 1940. School performance of children receiving amphetamine (Benzedrine) sulfate. Am J Orthopsychiatry 10:782–788.
Brondum-NielsenK, TommerupN, FriisB, HjeltK, HippeE. 1983. Folic acid metabolism in a patient with fragile X. Clin Genet 30:45–47.
BrozoskiT, BrownRM, RosvoldHE, GoldmanPS. 1979. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 205:929–931.
CampbellIC, TodrickA. 1973. On the pharmacology and biochemistry of the amine-uptake mechanism in human blood platelets. Br J Pharmacol 49:279–287.
CarpenterLL, AndersonGM, PeltonGHet al. 1998. Tryptophan depletion during continuous CSF sampling in healthy human subjects. Neuropsychopharmacology 19:26–35.
CastellanosFX, EliaJ, KruesiMJPet al. 1996. Cerebrospinal homovanillic acid predicts behavioral response to stimulants in 45 boys with attention-deficit hyperactivity disorder. Neuropsychopharmacology 14:125–137.
ClaudeD, FirestoneP. 1995. The development of ADHD boys: a 12 year follow-up. Can J Behav Sci 27:226–249.
ConnorDF. 2006. Stimulants. In Attention-Deficit Hyperactivity Disorder. BarkleyRA, ed. New York, NY: Guilford Press, pp. 608–647.
ConnorDF, SteingardRJ. 2004. New formulations of stimulants for attention-deficit hyperactivity disorder: therapeutic potential. CNS Drugs 18:1011–1030.
CornishK, TurkJ, HagermanR. 2008. The fragile X continuum: new advances and perspectives. J Intellect Disabil Res 52:469–482.
DunnHG, RenpenningH, GerrardJWet al. 1963. Mental retardation as a sex-linked defect. Am J Ment Defic 67:827–848.
FullerRW, PerryKW, BymasterFP, WongDT. 1978. Comparative effects of pemoline, amfoelic acid, and amphetamine on dopamine uptake and release in vitro on brain 3,4-dihydroxyphenylacetic acid concentration on spiperone-treated rats. J Pharm Pharmacol 30:197–198.
HagermanRJ. 2002. Medical follow-up and pharmacotherapy. In Fragile X Syndrome: Diagnosis, Treatment, and Research, 3rd edn. HagermanRJ, HagermanPJ, eds. Baltimore, MD: The Johns Hopkins University Press, pp. 136–168.
HagermanRJ, JacksonAW, LevitasAet al. 1986. Oral folic acid versus placebo in the treatment of males with the fragile X syndrome. Am J Med Genet 23:241–262.
HarpeyJP. 1982. Treatment of fragile X. Pediatrics 69:670.
HerbstD, MillerJ. 1980. Nonspecific X-linked mental retardation. II. The frequency in British Columbia. Am J Med Genet 7:461–469.
JacobsP, GloverT, MayerM. 1980. X-linked mental retardation: a study of seven families. Am J Med Genet 7:471–489.
JohnsonGE. 1897. Contribution to the psychology and pedagogy of feeble-minded children. J Psycho-asthenics 2:26–32.
KesslerRC, ChinWT, DemlerO, WaltersEE. 2005. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617–627.
KingBH, HollanderE, SikichLet al. 2009. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 66:583–590.
KornetskyC. 1970. Psychoactive drugs in the immature organism. Psychopharmacologia 17:105–136.
KuczenskiR. 1983. Biochemical actions of amphetamines and other stimulants. In Stimulants: Neurochemical, Behavior, and Clinical Perspectives. CreaseI, ed. New York, NY: Raven Press, pp. 31–63.
LangerDH, RapoportJL, BrownGL, EbertMH, BunneyWE Jr. 1982. Behavioral effects of carbidopa/levodopa in hyperactive boys. J Am Acad Child Psychiatry 21:10–18.
LeboyerM, PhilippeA, BouvardMet al. 1999. Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. Biol Psychiatry 45:158–163.
LehrkeRG. 1974. X-linked mental retardation and verbal disability. In Birth Defects: Original Article Series. BergsmaD, ed. New York, NY: National Foundation, pp. 1–100.
LejeuneJ. 1981. Metabolisme des monocarbones et syndrome de l'X fragile. Bull Acad Natl Med (Paris) 165:1197–1206.
LejeuneJ. 1982. Is the fragile X syndrome amenable to treatment?Lancet 1:273–274.
LejeuneJ, RethoreMO, de BloisMC, RavelA.Trial of folic acid treatment in fragile X syndrome. 1984. Ann Genet 27:230–232.
LoeschDZ, HugginsRM, HagermanRJ. 2004. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev 10:31–41.
LosowskyMS. 1961. Hereditary mental defect showing the pattern of sex influence. J Ment Defic Res 5:60–62.
LubsHA. 1969. A marker X chromosome. Am J Hum Genet 21:231–244.
MartinJP, BellJ. 1943. A pedigree of mental defect showing sex linkage. J Neurol Psychiatry 6:154–157.
McBrideSM, ChoiCH, WangYet al. 2005. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 45:753–764.
McDougleCJ, KreschL, PoseyDJ. 2000. Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors. J Autism Dev Disord 30:427–435.
McDougleCJ, NaylorST, CohenDJet al. 1996. Effects of tryptophan depletion in drug-free adults with autistic disorder. Arch Gen Psychiatry 53:993–1000.
McDougle CJ, NaylorST, CohenDJet al. 1996. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001–1008.
MikkelsenE, LakeRC, BrownGL, ZieglerMG, EbertMH. 1981. The hyperactive child syndrome: peripheral sympathetic nervous system function and the effect of d-amphetamine. Psychiatry Res 4:157–169.
MolitchM, EcclesAK. 1937. Effect of benzedrine sulphate on intelligence scores of children. Am J Psychiatry 94:587–590.
PenroseLS. 1938. A clinical and genetic study of 1,280 cases of mental defect. Ment Res Council Special Report; Ser. 229.
PierettiM, ZhangFP, FuYHet al. 1991. Absence of expression of the FMR1 gene in fragile X syndrome. Cell 66:817–822.
PliszkaSR. 1987. Tricyclic antidepressants in the treatment of children with attention deficit disorder. J Am Acad Child Adolesc Psychiatry 26:127–132.
PliszkaSR. 2005. The neuropsychopharmacology of attention-deficit/hyperactivity disorder. Biol Psychiatry 57:1385–1390.
PliszkaSR, McCrackenJT, MaasJW. 1996. Catecholamines in attention deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 35:264–272.
PopovichBW, RosenblattDS, CooperBA, VekemansM. 1983. Intracellular folate distribution in cultured fibroblasts from patients with fragile X syndrome. Am J Hum Genet 35:869–878.
RenpenningH, GerrardJW, ZaleskiA, TabataT. 1962. Familial sex-linked mental retardation. Can Med Assoc J 87:954–956.
RichardsBW, SylvesterPE, BrookerC. 1981. Fragile X-linked mental retardation: the Martin-Bell syndrome. J Ment Defic Res 25:253–256.
RitvoER, YuwilerA, GellerEet al. 1970. Increased blood serotonin and platelets in early infantile autism. Arch Gen Psychiatry 23:566–572.
RogersSJ, WehnerDE, HagermanR. 2001. The behavioral phenotype in fragile X: symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. J Dev Behav Pediatr 22:409–417.
SchainRJ, FreedmanDX. 1961. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr 58:315–320.
ShaywitzSE, CohenDJ, BowersMB Jr. 1977. CSF monoamine metabolites in children with minimal brain dysfunction: evidence for alteration of brain dopamine. J Pediatr 90:67–71.
ShermanS. 2002. Epidemiology. In Fragile X Syndrome: Diagnosis, Treatment, and Research, 3rd edn. HagermanRJ, HagermanPJ, eds. Baltimore, MD: The Johns Hopkins University Press, pp. 136–168.
ShettyT, ChaseTN. 1976. Central monoamines and hyperactivity of childhood. Neurology 26:1000.
SnyderRD, RobinsonA. 1969. Recessive sex-linked mental retardation in the absence of other recognizable abnormalities. Clin Pediatr 8:669–674.
SolantoMV. 1998. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 94:127–152.
SpencerTJ. 2006. Antidepressant and specific norepinephrine reuptake inhibitor treatments. In Attention-Deficit Hyperactivity Disorder. BarkleyRA, ed. New York, NY: Guilford Press, pp. 648–657.
SpencerT, BiedermanJ, WilensTet al. 1996. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35:409–432.
StillGF. 1902. Some abnormal psychical conditions in children. Lanceti:1008–1012, 1077–1082, 1163–1168.
StromCM, BruscaRM, PizziWJ. 1992. Double-blind, placebo-controlled crossover study of folinic acid (Leucovorin) for the treatment of fragile X syndrome. Am J Med Genet 44:676–682.
SutherlandGR. 1977. Fragile sites on human chromosomes: demonstration of their dependence on the type of tissue culture medium. Science 197:265–266.
SutherlandGR. 1979 a. Heritable fragile sites on human chromosomes. I. Effect of composition of culture media on expression. Am J Hum Genet 31:125–135.
SutherlandGR. 1979 b. Heritable fragile sites on human chromosomes. II. Distribution, phenotypic effects and cytogenetics. Am J Hum Genet 31:136–148.
SutherlandGR. 2003. Rare fragile sites. Cytogenet Genome Res 100:77–84.
SutherlandGR, AshforthPL. 1979. X-linked mental retardation with macro-orchidism and the fragile site at Xq27 or 28. Hum Genet 48:117–120.
SutherlandGR, BasilicoC. 1966. Infection of thymidine kinase-deficient BHK cells with polyoma virus. Nature 211:250–252.
TassoneF, HagermanRJ, IkleDNet al. 1999. FMRP expression as a potential prognostic indicator in fragile X syndrome. Am J Med Genet 84:250–261.
TredgoldAF. 1908. Mental Deficiency (Amentia ). New York, NY: William Wood.
TurnerG, DanielA, FrostM. 1980. X-linked mental retardation, macroorchidism and the Xq27 fragile site. J Pediatr 96:836–841.
TurnerG, TillR, DanielA. 1978. Marker X chromosomes, mental retardation and macroorchidism. N Engl J Med 299:1472.
VenterPA, GerickeGS, DawsonB, Op't HofJ. 1981. A marker X chromosome associated with nonspecific male mental retardation. S Afr Med J 21:807–811.
WangJCC, ErbeRW. 1984. Folate metabolism in cells from fragile X syndrome patients and carriers. Am J Med Genet 17:303–310.
Whitaker-AzmitiaPM. 1993. The role of serotonin and serotonin receptors in development of the mammalian nervous system. In Receptors in the Developing Nervous System, Vol. 2, Neurotransmitters. ZagonIS, McLaughlinPJ, eds. London: Chapman & Hall, pp.43–53.
YanQJ, RammalM, TranfagliaM, BauchwitzRP. 2005. Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49:1053–1066.
ZametkinAJ, RapoportJL. 1987. Neurobiology of attention deficit disorder with hyperactivity: where have we come in 50 years?J Am Acad Child Adolesc Psychiatry 26:676–686.
ZametkinAJ, RapoportJL, MurphyDLet al. 1985. Treatment of hyperactive children with monoamine oxidase inhibitors. II. Plasma and urinary monoamine findings after treatment. Arch Gen Psychiatry 42:969–973.